- Home
- XPEL vs SPRY Comparison
XPEL vs SPRY Comparison
Compare XPEL & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XPEL
- SPRY
- Stock Information
- Founded
- XPEL 1999
- SPRY 2015
- Country
- XPEL United States
- SPRY United States
- Employees
- XPEL N/A
- SPRY N/A
- Industry
- XPEL Industrial Specialties
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- XPEL Industrials
- SPRY Health Care
- Exchange
- XPEL Nasdaq
- SPRY Nasdaq
- Market Cap
- XPEL 999.3M
- SPRY 1.6B
- IPO Year
- XPEL N/A
- SPRY N/A
- Fundamental
- Price
- XPEL $39.34
- SPRY $16.95
- Analyst Decision
- XPEL Strong Buy
- SPRY Strong Buy
- Analyst Count
- XPEL 1
- SPRY 4
- Target Price
- XPEL $58.00
- SPRY $28.75
- AVG Volume (30 Days)
- XPEL 170.8K
- SPRY 1.5M
- Earning Date
- XPEL 08-07-2025
- SPRY 08-05-2025
- Dividend Yield
- XPEL N/A
- SPRY N/A
- EPS Growth
- XPEL N/A
- SPRY N/A
- EPS
- XPEL 1.71
- SPRY N/A
- Revenue
- XPEL $434,101,000.00
- SPRY $97,122,000.00
- Revenue This Year
- XPEL $11.20
- SPRY N/A
- Revenue Next Year
- XPEL $11.18
- SPRY $140.40
- P/E Ratio
- XPEL $22.94
- SPRY N/A
- Revenue Growth
- XPEL 8.38
- SPRY 971120.00
- 52 Week Low
- XPEL $24.25
- SPRY $8.77
- 52 Week High
- XPEL $48.58
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- XPEL 65.72
- SPRY 55.33
- Support Level
- XPEL $35.40
- SPRY $15.75
- Resistance Level
- XPEL $36.61
- SPRY $18.90
- Average True Range (ATR)
- XPEL 1.19
- SPRY 1.04
- MACD
- XPEL 0.15
- SPRY 0.01
- Stochastic Oscillator
- XPEL 97.34
- SPRY 49.26
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.